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FORUM ORIGINAL RESEARCH COMMUNICATION
Adrenergic Signaling Regulates Mitochondrial Ca2+ Uptake
Through Pyk2-Dependent Tyrosine Phosphorylation
of the Mitochondrial Ca2+ Uniporter
Jin O-Uchi,1,* Bong Sook Jhun,1,* Shangcheng Xu,2 Stephen Hurst,1 Anna Raffaello,3 Xiaoyun Liu,2 Bing Yi,1
Huiliang Zhang,2 Polina Gross,1 Jyotsna Mishra,1 Alina Ainbinder,4 Sarah Kettlewell,5 Godfrey L. Smith,5
Robert T. Dirksen,4 Wang Wang,2 Rosario Rizzuto,3 and Shey-Shing Sheu1
Abstract
Aims: Mitochondrial Ca2+ homeostasis is crucial for balancing cell survival and death. The recent discovery of
the molecular identity of the mitochondrial Ca2+ uniporter pore (MCU) opens new possibilities for applying
genetic approaches to study mitochondrial Ca2+ regulation in various cell types, including cardiac myocytes. Basal
tyrosine phosphorylation of MCU was reported from mass spectroscopy of human and mouse tissues, but the
signaling pathways that regulate mitochondrial Ca2+ entry through posttranslational modifications of MCU are
completely unknown. Therefore, we investigated a1-adrenergic-mediated signal transduction of MCU posttrans-
lational modification and function in cardiac cells. Results: a1-adrenoceptor (a1-AR) signaling translocated acti-
vated proline-rich tyrosine kinase 2 (Pyk2) from the cytosol to mitochondrial matrix and accelerates mitochondrial
Ca2+ uptake via Pyk2-dependent MCU phosphorylation and tetrametric MCU channel pore formation. Moreover,
we found that a1-AR stimulation increases reactive oxygen species production at mitochondria, mitochondrial
permeability transition pore activity, and initiates apoptotic signaling via Pyk2-dependent MCU activation and
mitochondrial Ca2+ overload. Innovation: Our data indicate that inhibition of a1-AR-Pyk2-MCU signaling rep-
resents a potential novel therapeutic target to limit or prevent mitochondrial Ca2+ overload, oxidative stress,
mitochondrial injury, and myocardial death during pathophysiological conditions, where chronic adrenergic
stimulation is present. Conclusion: The a1-AR-Pyk2-dependent tyrosine phosphorylation of the MCU regulates
mitochondrial Ca2+ entry and apoptosis in cardiac cells. Antioxid. Redox Signal. 21, 863–879.
Introduction
M itochondrial Ca
2+ homeostasis determines numer-
ous cell functions, including energy metabolism, re-
active oxygen species (ROS) generation, spatiotemporal
dynamics of Ca2+ signaling, cell growth/development, and
death (19, 24, 56, 57). The mitochondrial Ca2+ uniporter
(mtCU), which is inhibited by lanthanides and ruthenium red
(26), is the primary mechanism for mitochondrial Ca2+ influx
in all cell types (8). Although functionally characterized
several decades ago (18, 56), the complete molecular identity
of the mtCU has yet to be fully elucidated. However,
groundbreaking studies recently uncovered the molecular
identity of the mtCU pore (MCU), the coiled-coil domain-
containing protein 109A (CCDC109A) (3, 14), as well as the
regulatory proteins (56). These findings open up exciting
new opportunities for using genetic approaches to elucidate
mechanisms that regulate mitochondrial Ca2+ uptake in
various cell types, including cardiac myocytes (17). For ex-
ample, basal tyrosine phosphorylation of CCDC109A was
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reported from mass spectroscopy analyses of human and
mouse samples (see online database PhosphoSitePlus) (33).
However, specific signaling pathways that control mito-
chondrial Ca2+ entry through posttranslational modifications
of MCU are completely unknown.
In cardiac cells, adrenoceptor (AR) stimulation, either
through b- or a1-ARs, is a main determinant of physiological
and pathophysiological cell signaling, predominantly through
serine/threonine kinases [e.g., protein kinase A and Ca2+ /
calmodulin-dependent protein kinase II (CaMKII)](55). In
addition, we reported that protein tyrosine kinases (PTKs) are
also activated during a1-AR stimulation (a1-ARS) in cardiac
myocytes (54), and another report showed that a Ca2+ -
dependent PTK named proline-rich tyrosine kinase 2 (Pyk2) is
activated in response to a1-ARS (27). Pyk2 is expressed
abundantly in cancers (42, 42). However, a recent study using
human tissue showed that Pyk2 is also highly expressed in the
heart and significantly activated during heart failure (40).
Moreover, several reports indicate that Pyk2 is not only
localized in the cytosol, but also in mitochondria (1, 23).
Therefore, we hypothesize that a1-AR-Pyk2 signaling regu-
lates mitochondrial Ca2+ entry through MCU tyrosine phos-
phorylation in cardiac cells.
In this study, we report that Pyk2 activated by a1-AR
signaling directly phosphorylates MCU, which enhances
mitochondrial Ca2+ uptake by promoting MCU channel
oligomerization and formation of tetrameric channels.
Moreover, we demonstrate that a1-ARS and Pyk2 activation
initiates ROS production in mitochondria (mitochondrial
ROS: mROS), the activity of mitochondrial permeability
transition pore (mPTP), apoptotic signaling, and cardio-
myocyte death. This study is the first to show the modulation
of MCU by adrenergic signaling and the regulation of ROS
generation and cell death signaling via a posttranslational
modification of MCU in cardiac cell.
Results
a1-AR stimulation accelerates mitochondrial Ca
2+ uptake
To explore whether adrenergic signaling regulates mito-
chondrial Ca2+ uptake in cardiac cells, wemonitored changes
in the mitochondrial matrix Ca2+ concentration ([Ca2+ ]mt) by
expressing Mitycam, a mitochondria-targeted Ca2+ -sensitive
inverse pericam (39, 53), in intact cardiac H9c2 myoblasts
(Fig. 1). In this cell, Mitycam localized exclusively in mi-
tochondria by cotransfecting with mitochondrial matrix-
targeted RFP (53) (mt-RFP) (Fig. 1A, B). We observed the
peak amplitude of the changes in Mitycam fluorescence
(decrease in Mitycam fluorescence) to evaluate the magni-
tude of mitochondrial Ca2+ uptake (39, 53) (see also online
Materials and Methods section). The changes in the cytosolic
Ca2+ concentration ([Ca2+ ]c) were also monitored by Fura-
red (53) (Fig. 1 and Supplementary Fig. S1; Supplementary
Data are available online at www.liebertpub.com/ars).
Mitycam responded to elevations in [Ca2+ ]mt in response to
[Ca2+ ]c elevations induced by an inhibitor of the sarco/
endoplasmic Ca2+ -ATPase (SERCA), thapsigargin (TG,
3 lM) (41) (Fig. 1D and Supplementary Fig. S2). The in-
crease in [Ca2+ ]mt observed in response to an elevation in
cytosolic Ca2+ induced by TG was almost abolished by ex-
pression of a dominant-negative pore-forming subunit of
MCU (MCUB) (63), confirming theMCU dependence of this
mitochondrial Ca2+ uptake (Fig. 1D–G). In addition, a sig-
nificant increase in [Ca2+ ]c was detected in cells over-
expressing MCUB due to reduced mitochondrial buffering
Innovation
This report is the first to show the regulation of mito-
chondrial Ca2 + uptake, reactive oxygen species genera-
tion, and cell death signaling via mitochondrial Ca2+
uniporter pore (MCU) posttranslational modification. Our
data provide significant and broad implications for un-
derstanding the regulation of MCU in cell signaling across
all cell types, including cardiomyocytes. In addition, the
results from this study suggest that inhibition of MCU
tyrosine phosphorylation represents a potential, novel
therapeutic target to prevent mitochondrial Ca2+ overload,
oxidative stress, and mitochondrial/cell injury.
FIG. 1. a1-adrenoceptor (a1-AR) stimulation accelerates mitochondrial Ca
21 uptake in H9c2 cells. (A) Expression of
mitochondria-targeted Ca2+ -sensitive probe, Mitycam. Mitochondrial location was determined using mt-RFP. A cell stably
transfected with only mt-RFP is also shown in the top row to confirm almost no background fluorescence in the GFP channel.
Mitycam localized to mitochondria. Scale bars, 20lm. (B) Color scatter plotting (right) and frequency scatter plotting (left)
obtained from representative pictures in (A). (C) Time course of Mitycam fluorescence intensity during 3lM thapsigargin
(TG) treatment. Scale bar, 10lm. (D) Left: Representative time courses of [Ca2+ ]mt (top) and [Ca
2+ ]c (bottom) in cells
stimulated by TG in control cells (CTR: nontransfected cells) (black), MCU (red), and MCUB (blue)-overexpressed cells.
Arrow indicates TG application. [Ca2+ ]mt and [Ca
2+ ]c were measured using Mitycam and Fura-Red, respectively. Mitycam
fluorescence (F) was converted into 1 - (DF/F0), which shows the changes in [Ca2+ ]mt, where Fo stands for initial
fluorescence levels. Averaged data are shown in Supplementary Fig. S2. Right: summary data of left panels. [Ca2+ ]mt was
measured at 60 s after stimulation. For [Ca2+ ]c, peak [Ca
2+ ]c within 120 s was measured. *p< 0.05, compared to CTR. (E)
Effect of Phe pretreatment on [Ca2+ ]mt and [Ca
2+ ]c. Representative time course of [Ca
2+ ]mt (top) and [Ca
2+ ]c (bottom) after
TG stimulation (arrow) in cells with (red) or without (black) pretreatment with Phe (100lM, 15min). [Ca2+ ]mt and [Ca
2+ ]c
were simultaneously measured using Mitycam and Fura-red, respectively, in a single cell (see Supplementary Materials and
Methods section). Summary data are shown in Supplementary Fig. S5. (F) Left: Averaged time course of [Ca2+ ]mt after TG
stimulation (arrow) in cells with (red) or without (black) pretreatment with Phe (100lM, 15min). [Ca2+ ]mt in cells over-
expressing MCU-DN (blue) or MCUB (sky blue) is also shown for comparison. Right: Averaged time course of [Ca2+ ]mt after
TG stimulation (arrow) in MCU-transfected cells pretreated with (red) or without (black) Phe. (G) Summary data of (F) at 60 s
after stimulation. [Ca2+ ]mt in cell pretreatment with Phe and prazosin (Praz, 1lM) ( purple) is also shown (see also Sup-
plementary Fig. S5). *p< 0.05, compared to CTR without Phe treatment. #p< 0.05, N.S., not significant. To see this illustration
in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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(Fig. 1D and Supplementary Fig. S2). On the other hand, the
increase in [Ca2+ ]mt in response to TG was enhanced and a
significant reduction in the [Ca2+ ]c in response to TG was
observed in MCU overexpressing cells (Fig. 1D–G and
Supplementary Fig. S2). This greater mitochondrial response
was not secondary to alterations of the cytosolic response, but
a rather significant reduction in the [Ca2+ ]c transient was
observed, due to the increased Ca2+ clearance by mito-
chondria, consistent with previous reports (3, 14, 17).
To test whether a1-ARS regulates mitochondrial Ca
2+
uptake, changes in [Ca2+ ]mt and [Ca
2+ ]c induced by TG were
simultaneously measured in cells pretreated for 15min with
the a1-AR agonist phenylephrine (Phe, 100 lM). In H9c2
cells, not like other Gq-protein-coupled receptors (GqPCR)
expressed in this cell line (41, 53, 59), acute Phe treatment did
not induce global cytosolic Ca2+ elevation indicating a lack
of Ca2+ release from the sarco/endoplasmic reticulumin (SR/
ER) through inositol 1,4,5-trisphosphate (IP3) receptor
(Supplementary Fig. S1), possibly due to the lower endoge-
nous expression levels of a1-AR and subsequent IP3 gener-
ation upon stimulation (Supplementary Fig. S3) in this cell
line. Phe was able to activate downstream signaling equiva-
lent to other GqPCR agonists (Supplementary Fig. S4). TG
induced a higher [Ca2+ ]mt increase in Phe-pretreated cells
compared with untreated cells (Fig. 1E, F). A significant re-
duction in the [Ca2+ ]c transient was also observed, due to the
increased Ca2+ clearance by mitochondria (Fig. 1E and
Supplementary Fig. S5). The increase in [Ca2+ ]mt observed in
Phe-pretreated cells was almost abolished in the presence of
the a1-AR antagonist prazosin (1lM), confirming that this
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effect is mediated through a1-ARS (Fig. 1G and Supple-
mentary Fig. S5). Interestingly, peak [Ca2+ ]mt in Phe-treated
cells reached similar levels as that observed in MCU over-
expressing cells without Phe pretreatment (Fig. 1F, G).
We also observed the concentration-dependent effect of
Phe on [Ca2+ ]mt elevation. Half maximal effective concen-
tration of Phe was y2lM (Supplementary Fig. S5). In ad-
dition, to test whether b-AR stimulation, which is the major
AR isoform in cardiomyocytes, regulates mitochondrial Ca2+
uptake, TG-induced [Ca2+ ]mt changes were measured in cells
pretreated for 15min with the b-AR agonist isoproterenol
(Iso, 1 lM). In Iso-pretreated cells, the increase in [Ca2+ ]mt
was similar to that in nontreated cells, indicating that this
effect is specific to a1-AR signaling (Supplementary Fig. S5).
In cells expressing MCUB (63) or a dominant-negative MCU
mutant (MCU-DN) (14), TG-induced [Ca2+ ]mt uptake was
significantly reduced and Phe pretreatment did not augment
this uptake, demonstrating that Phe stimulation enhances
MCU function (Fig. 1F–G). On the other hand, in MCU
overexpressing cells, TG-induced [Ca2+ ]mt uptake reached
higher levels following Phe pretreatment (Fig. 1F, G). We
also confirmed that in native cultured rat neonatal cardio-
myocytes (NCMs), a1-AR signaling (pretreatment of Phe or a
physiological agonist, norepinephrine) can accelerate mito-
chondrial Ca2+ uptake (Supplementary Fig. S6). Thus, a1-
ARS upregulates mitochondrial Ca2+ uptake by augmenting
MCU function.
a1-AR stimulation triggers activated Pyk2 translocation
from cytosol to mitochondria and MCU
tyrosine phosphorylation
The next question is how a1-ARS can activate MCU func-
tion. Our hypothesis is that activated Pyk2 by a1-ARS phos-
phorylates MCU and accelerates mitochondrial Ca2+ uptake.
To begin with, we first established a HEK293T cell line stably
overexpressing MCU (HEK293T-MCU-Flag cells) to cir-
cumvent potential issues related to low endogenous expression
ofMCU in cultured cells (3, 14) (Fig. 2).We found that a small
amount of endogenous Pyk2 was present in mitochondria-
enriched fractions and a1-ARS increased the amount of mi-
tochondrial Pyk2 (namedmPyk2) (Fig. 2A).We quantitatively
analyzed the ratio of cytosolic and mitochondrial Pyk2 and
found that Pyk2 translocated from the cytosol to mitochondria
upon Phe stimulation (Fig. 2A). In addition, the amount of
activated Pyk2 (autophosphorylated Pyk2) was significantly
increased in mitochondria-enriched fraction after a1-ARS,
possibly due to the significant activated Pyk2 translocation
from the cytosol to mitochondria (Fig. 2A, B). GqPCR sig-
naling, including a1-AR, increases ROS (20) and Pyk2 is
known to be activated by ROS (22). Consistent with this
mechanism, pretreatment with an antioxidant, N-acetylcysteine
or amitochondria-targeted antioxidant,mito-TEMPO [a specific
scavenger of mitochondrial superoxide (mSO)] (73) signifi-
cantly inhibited a1-AR-mediated activated Pyk2 translocation
from cytosol to mitochondria (Fig. 2A, B and Supplementary
Fig. S7). We next used the anti-phosphotyrosine (-P-Tyr)
antibody and observed tyrosine phosphorylation of MCU in
mitochondria-enriched fraction after Phe stimulation. The in-
tensity of a P-Tyr band identical to the molecular weight of
MCU was significantly increased after Phe stimulation, indi-
cating that tyrosine residue(s) in MCUmight be phosphorylated
after mPyk2 activation (Fig. 2B).
To investigate whether Pyk2 could directly phosphorylate
MCU, we determined the submitochondrial localization of
Pyk2 using Proteinase K (PK) digestion with a series of de-
tergent concentrations to differentially permeabilize the outer
mitochondrial membranes (OMM) and inner mitochondrial
FIG. 2. a1-AR stimulation induces activated Pyk2 translocation from cytosol in mitochondria and tyrosine phos-
phorylation of MCU in HEK293T cells. (A) Right: Pyk2 activation in HEK293T cells stably overexpressing MCU-Flag after
100lM Phe (15min), HEK293T cells stably overexpressing MCU-Flag were treated by 100lM Phe for 15min and whole cell
lysates (WCL) were prepared. Proteins were separated by SDS-PAGE (50lg/well). Activated Pyk2 was detected using the anti-
phospho-Tyr402-Pyk2 (p-Pyk2) antibody (see Supplementary Materials and Methods section). Summary data are shown at the
bottom. *p<0.05. Left: Pyk2 translocation into mitochondria in HEK293T cells stably overexpressing MCU-Flag after 100lM
Phe (15min). HEK293T cells stably overexpressing MCU-Flag were treated by 100lM Phe for 15min in the presence of absence
of N-acetylcysteine (NAC) and mitochondria-enriched fraction (Mito) and cytosolic fraction (including ER/SR) were prepared.
Proteins were separated by SDS-PAGE (12.5lg/well for each fractionated protein). Summary data are shown at the bottom.
*p<0.05. (B) Pyk2 activation and MCU phosphorylation in mitochondrial fractionation (50lg/well). To increase the signals from
P-Pyk2 and Pyk2, 50lg protein of mitochondria-enriched fraction was loaded in each well. MCU phosphorylation was detected
by anti-P-Tyr antibody. MCU phosphorylation was estimated by the P-Tyr bands identical to the molecular weight of MCU.
*p<0.05. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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membranes (IMM) (11). Proteins with known localization are
immunoblotted and labeled according to their topology
(Supplementary Fig. S8). Similar to the matrix protein cy-
clophilin D (Cyp-D), MCU is resistant to PK proteolysis even
under high digitonin concentrations (up to 0.1%), consistent
with the idea that MCU termini face to the matrix side. All
these proteins, including Cyp-D andMCU, were substrates of
PK as evidenced by significant digestion in the presence of
Triton X-100. In addition, Pyk2 was also digested only with
high digitonin, suggesting that endogenous mPyk2 primarily
exists in the matrix and/or is bound to IMM from the matrix
side at resting conditions. Interestingly, higher concentra-
tions of digitonin were required to digest Pyk2 after Phe
stimulation, suggesting that the amount of matrix mPyk2
increases after Phe stimulation (Supplementary Fig. S8).
Next, we confirmed that Pyk2 could specifically and directly
bind toMCU and phosphorylate MCU by in vitro binding (72)
and kinase assays (37) using purified MCU and Pyk2 proteins
(Fig. 3A, B). The MCU-Pyk2 interaction and Pyk2-dependent
phosphorylation of MCU were also observed in situ by im-
munoprecipitation (IP) in whole cell lysates (WCL) (Fig. 3C,
D) or mitochondrial-enriched protein fractions (Fig. 3E). The
MCU-Pyk2 interaction was enhanced after Phe stimulation
concomitant with MCU phosphorylation (Fig. 3D, E). The
MCU phosphorylation by Phe was inhibited by pretreatment
with Mito-TEMPO, confirming that this mechanism is mROS
dependent (Supplementary Fig. S7). Moreover, these effects
were abolished by expression of a kinase-dead Pyk2 mutant
(Pyk2-KD) (Supplementary Fig. S9) or transfection of siRNA
targeted to Pyk2 (siRNA-Pyk2) (Fig. 3F, G).
Together, these results demonstrate that mPyk2 is acti-
vated by a1-AR-dependent and mROS-dependent signaling,
which leads to mPyk2 binding to MCU and direct phos-
phorylation of MCU in the matrix.
Next, we tested whether this a1-AR-Pyk2-MCU signaling
cascade also exists in H9c2 cells. Pyk2 activation, Pyk2
translocation into mitochondria, MCU-Pyk2 interaction, and
Pyk2-dependent MCU phosphorylation were detected in this
cell line (Fig. 4A–D), similar to those observed in HEK293T
cells. We also observed Pyk2 translocation into mitochondria
using confocal microscopy under Phe stimulation by co-
transfection of GFP-Pyk2 and MCU-DsRed (Fig. 4E). Pyk2
localized in both the cytosol and mitochondria at baseline.
After Phe stimulation, a more punctate pattern of GFP-Pyk2
was observed indicating mitochondrial localization. Over-
lapped coefficiency (37, 53) was increased indicating GFP-
Pyk2 translocation into mitochondria and colocalization with
MCU-RFP after Phe stimulation (Fig. 4E). We also per-
formed Fo¨rster resonance energy transfer (FRET) analysis by
imaging the combination of GFP-Pyk2 (donor) and MCU-
DsRed (acceptor) to determine the interaction of these two
molecules in situ (Fig. 4F, G). The FRET signal from GFP-
Pyk2/MCU-Dsred at rest was higher than that observed from
the cells coexpressing GFP and MCU-Dsred, suggesting that
there is a specific interaction of Pyk2 and MCU in situ (Fig.
4F). After Phe stimulation, the FRET signal from GFP-Pyk2/
MCU-Dsred increased in a time-dependent manner (Fig. 4G).
These data demonstrate that a1-ARS triggers activated Pyk2
translocation from cytosol to mitochondria, where it interacts
with MCU and phosphorylates MCU in H9c2 cells.
We next asked whether this signaling also occurs in
native cardiomyocytes. In native cardiomyocytes, a high
dose of Phe (>10 lM) shows less receptor specificity and
activates not only a1-AR signaling but also nonselectively
activates b-AR signaling due to the high expression level
of b-AR (58). Therefore, we used a b-AR antagonist, 1 lM
propranolol in the extracellular solution for stimulation of
native cardiomyocytes with Phe to block the contamination
of b-AR effects (58). In NCMs, activated Pyk2 was
translocated from cytosol to mitochondria and phosphor-
ylated MCU during Phe (Fig. 5A–C). In isolated rat adult
cardiomyocytes (ACMs), Pyk2 was also activated and
phosphorylates MCU upon a1-ARS (Fig. 5D, E). These
effects in NCMs and ACMs were abolished by pretreat-
ment of a1-AR antagonist, prazosin, or focal adhesion ki-
nase (FAK)/Pyk2 selective inhibitor, PF-431396 (Fig. 5).
Collectively, Pyk2 is activated by a1-ARS, imported into
mitochondria and directly phosphorylates MCU in native
cardiomyocytes.
a1-AR-Pyk2 signaling regulates MCU channel
oligomerization and function
We next addressed the mechanism by which Pyk2-
dependent MCU phosphorylation activates MCU-dependent
mitochondrial Ca2+ uptake. A single MCU protein con-
tains two transmembrane domains and MCU needs to be oli-
gomerized to form channels (14, 63). Therefore, our next
hypothesis is that Pyk2-dependent MCU phosphorylation en-
hances MCU oligomerization (i.e., channel pore formation).
At first,MCU-GFPwas transfected intoHEK293T-MCU-Flag
cells (Supplementary Fig. S10). After Phe stimulation, binding
of MCU-GFP and MCU-Flag was significantly increased after
Phe stimulation, suggesting that interaction of MCU mono-
mers with different tags was enhanced by a1-ARS in situ to
form a higher order complex (Supplementary Fig. S10). Next,
we performed conventional native gel separation of whole
cell lysates from HEK293T-MCU-Flag cells and found that
MCU migrated at a molecular weight of *140 kDa (Fig. 6).
The size of the MCU monomer and oligomer observed here
was consistent with our observation using wheat germ lysates
expressing MCU (63). The magnitude of this higher order
complex increased following 15min of Phe stimulation, which
was blocked by eitherMito-TEMPOor Pyk2-knockdown (Fig.
6B, C). Similar results were obtained using mitochondria-
enriched fractionation proteins (Supplementary Fig. S11).
These results indicate that a1-AR-Pyk2-dependent MCU
phosphorylation promotes MCU oligomerization.
Finally, we tested whether Pyk2 activation during a1-AR
enhances mitochondrial Ca2+ uptake in H9c2 cells using the
protocol shown in Figure 1. Pyk2 is known as a Ca2+ - and
ROS-dependent kinase, but 10min of TG treatment did not
activate Pyk2 in this cell line, confirming that our protocol for
triggering mitochondrial Ca2+ accumulation itself did not
significantly activate Pyk2 through increased [Ca2+ ]c (Sup-
plementary Fig. S12). The increase in [Ca2+ ]mt observed in
Phe-pretreated cells was abolished in the presence of PF-
431396, indicating that this effect is mediated by Pyk2 or
FAK activity (Fig. 7A, right). The treatment with PF-431396
itself did not change the peak [Ca2+ ]c (Fig. 7A, left). Next,
we transfected the plasmid containing siRNA-Pyk2 (67) into
H9c2 cells (Fig. 7B and Supplementary Fig. S13). The in-
crease in [Ca2+ ]mt observed in Phe-pretreated cells was
abolished in the cells transfected by siRNA-Pyk2, indicating
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that Pyk2 is necessary for this effect (Fig. 7B). Collectively,
these results show that a1-AR-Pyk2-dependent MCU tyro-
sine phosphorylation promotes MCU oligomerization,
leading to the facilitation of mitochondrial Ca2+ uptake
through MCU.
a1-AR-Pyk2 signaling triggers MCU-dependent ROS
generation and proapoptotic protein release
Excessive mitochondrial Ca2+ uptake increases ROS
production from mitochondria in cardiomyocytes (31). In
FIG. 3. Pyk2 binds to MCU and directly phosphorylates MCU. (A) In vitro kinase assay. Top: MCU-flag produced in
HEK293T cells stably overexpressing MCU-Flag was collected by IP and treated with Pyk2 kinase-domain peptide (active
Pyk2) (see Supplementary Materials and Methods section). Bottom: Summary data of MCU phosphorylation. *p < 0.05. (B)
Protein membrane overlay (in vitro binding) assay using GST-MCU and His-Pyk2 (see Supplementary Materials and
Methods section). His-Pyk2 specifically bound to GST-MCU (red) after overlay (middle panel), but His-kallikrein-1 (KLK-
1) (serine protease) did not (right panel). (see Supplementary Materials and Methods section). (C) In situ binding assay in
HEK293T cells transected with GFP-Pyk2 and MCU-flag. (D) In situ binding assay in HEK293T cells stably overexpressing
MCU-Flag. Top: IP was performed using. WCL before and after Phe stimulation. MCU phosphorylation was detected by
anti-P-Tyr antibody. Phosphorylation of MCU and interaction of MCU and Pyk2 significantly increased after Phe stimu-
lation. Bottom: Summary data of MCU phosphorylation and MCU/Pyk2 binding. *p < 0.05. (E) IP of mitochondria fraction
by anti-Flag (left) or anti-Pyk2 (right) antibodies. Nontransfected cells were used as control. *p < 0.05. (F) In situ binding
assay in HEK293T cells stably overexpressing MCU-Flag with or without Pyk2 knock down by siRNA-Pyk2. IP was
performed by anti-Flag antibody using WCL before and after Phe stimulation with or without Pyk2 knock down.
(G) Summary data of (F). To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars
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addition, mitochondrial Ca2+ overload results in mitochon-
drial membrane potential (DJm) depolarization, ROS over-
production, and release of the proapoptotic proteins into the
cytosol, ultimately resulting in cell injury and death. Our data
clearly showed that a1-AR-Pyk2 signaling strongly elevates
[Ca2+ ]mt (Figs. 1–7) and that this increase is maintained
at higher levels after a1-ARS. This sustained increase in
mitochondrial Ca2+ could significantly enhance mROS pro-
duction and apoptotic signals. Therefore, we tested whether
a1-ARS increases the mitochondrial levels of ROS in H9c2
cells using the mSO indicator MitoSOX-Red (53) (Fig. 8).
Basal MitoSOX-Red intensity was significantly decreased by
Mito-TEMPO pretreatment, confirming that MitoSOX-Red
is sensitive to mSO (Fig. 8B). We found that Phe treatment
significantly increased mSO levels and this effect was abol-
ished by the pretreatment of Mito-TEMPO (Fig. 8A, B).
Next, cells were pretreated by a potent FAK/Pyk2 inhibitor
PF-431396. Pretreatment of PF-431396 dramatically blocked
Phe-induced ROS increase (Fig. 8B). Moreover, we used the
cells transfected with siRNA-Pyk2 (Supplementary Fig. S13).
Basal MitoSOX-Red intensity in cells transfected by siRNA-
Pyk2 was significantly lower than that in cells treated with
control vector, indicating that Pyk2 is involved in the main-
tenance of basal mSO levels (Fig. 8B). Pyk2 knockdown
significantly blocked the Phe-induced increase in MitoSOX-
Red intensity, confirming that the increase in mSO levels by
FIG. 4. a1-AR stimulation activates Pyk2
and phosphorylates MCU in H9c2 cells. (A)
Top: Time-dependent activation of Pyk2 in
WCL during application of 100 lM Phe. Bot-
tom: Summary data of top panel. *p < 0.05
compared to nontreated cells (0min). (B) Top:
Pyk2 translocation from cytosol to mitochon-
dria by Phe stimulation (100lM, 15min).
Bottom: Summary data of top panels. *p < 0.05
compared to nontreated cells. (C) Left: IP of
WCL by anti-MCU antibody. Right: Quantita-
tive analysis of MCU phosphorylation after Phe
stimulation obtained from left panel. (D) Left:
IP of mitochondrial fractions by anti-MCU
antibody. Right: Quantitative analysis of
MCU phosphorylation after Phe stimulation
obtained from left panel. (E) Left: Time-
dependent GFP-Pyk2 translocation by Phe
stimulation (100lM, 30min) in a single cell.
Right: Summary data of overlapped coefficient
analysis before and after Phe stimulation (see
also Supplementary Materials and Methods
section). *p< 0.05. (F) Comparisons of FRET
efficiency between the cells expressing GFP-
Pyk2/MCU-DsRed and GFP/MCU-DsRed. FRET
efficiency was significantly higher in cells ex-
pressing GFP-Pyk2/MCU–DsRed. The ratio of
the emission intensity at 583 nm (DsRed) to
508 nm (GFP) represented FRET efficiency
(see Supplementary Materials and Methods
section). *p < 0.05. (G) Time-dependent chan-
ges in FRET efficiency after Phe stimulation
(100 lM, 30min) in cells expressing GFP-Pyk2
and MCU-DsRed (see Supplementary Materi-
als and Methods section). Cells stimulated by
vehicle (water) are shown as control. To see
this illustration in color, the reader is referred
to the web version of this article at www
.liebertpub.com/ars
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Phe was mediated through a1-AR-Pyk2 signaling. In addi-
tion, in cells overexpressing MCUB, MitoSOX-Red intensity
in basal conditions significantly decreased compared with
those in control cells and the Phe-induced increase in Mito-
SOX-Red intensity was completely abolished (Fig. 8B).
These results indicate that Phe stimulates mSO levels via a1-
AR-Pyk2-MCU signaling.
Because high levels of mROS trigger the release of mito-
chondrial intermembrane space proteins to the cytosol to
initiate apoptosis through increasing the OMM permeability
FIG. 5. a1-AR stimulation activates Pyk2 and phosphorylates MCU in native cardiomyocytes. (A) Neonatal cardio-
myocytes (NCMs) were treated by 100 lM Phe (in the presence of 1lM propranolol) for 15min with or without Pyk2
inhibitor (PF) and WCL were prepared. *p < 0.05 compared to the cells without stimulation (black). (B) Detection of MCU
tyrosine phosphorylation after IP by anti-MCU antibody using WCL. MCU phosphorylation was detected by anti-P-Tyr
antibody. p< 0.05 compared to the cells without stimulation (black). (C) Top: Pyk2 translocation and MCU phosphorylation
after Phe stimulation in NCMs. Bottom: Summary data. *p< 0.05 compared to the cells without stimulation (black). (D)
Top: Isolated adult cardiomyocytes (ACMs) were treated by 100lM Phe (in the presence of 1 lM propranolol) for 30min
with or without a1-AR antagonist prazosin (Praz) or Pyk2 inhibitor (PF) and WCL were prepared. Bottom: Summary data.
*p < 0.05. (E) Detection of MCU tyrosine phosphorylation after IP by anti-MCU antibody using WCL. p < 0.05 compared to
the cells without stimulation (black). To see this illustration in color, the reader is referred to the web version of this article
at www.liebertpub.com/ars
FIG. 6. a1-AR stimulation enhances the oligomerization of MCU via Pyk2 activation. (A) Representative Native
PAGE of WCL from HEK293T cells stably overexpressing MCU-Flag treated by Phe. Membranes were blotted with anti-
Flag antibody. MCU monomer bands in Native PAGE and SDS PAGE are shown with an arrow. MCU monomer bands in
SDS PAGE are shown as loading control. A higher band *140 kDa (smear distribution shown as a red square bracket),
which is compatible with a tetramer, indicating that MCU monomers were oligomerized in higher order complexes in situ.
(B) Mito-TEMPO pretreatment inhibits Phe-induced MCU oligomerization. MCU oligomerization (within a red square
bracket) was quantified by normalizing with MCU monomer in SDS-PAGE (bottom). *p < 0.05. N.S., not significant. (C)
Pyk2 knockdown inhibits Phe-induced MCU oligomerization (see also Fig. 3F, G). MCU oligomerization (within a red
square bracket) was quantified by normalizing with MCU monomer in SDS-PAGE (bottom). *p< 0.05. N.S., not significant.
To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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(e.g., by mPTP opening) (75), we determined whether a1-
ARS promotes proapoptotic protein release. We used a
fluorescence-tagged mitochondrial intermembrane space
protein, GFP-tagged second mitochondrial-derived activator
of caspase (Smac) to follow the time-dependent release of
proapoptotic proteins during a1-ARS (Fig. 8C–E) (49). We
analyzed changes in pixel intensity standard deviation
(punctate/diffuse index) as an index of Smac-GFP release
from mitochondria (49). The mitochondrial uncoupler car-
bonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP)
was used as a positive control to depolarize DJm to trigger
mPTP opening (15). After FCCP treatment, Smac-GFP re-
lease into the cytosol (monitored by the decrease in punctate/
diffuse index) was within 5min (Fig. 8C, D). Over 15–20min
of continuous stimulation, high-dose Phe releases a small
amount of Smac-GFP into the cytosol (Fig. 8C–E). Phe-
induced Smac-GFP release was completely blocked by either
the a1-AR antagonist prazosin, overexpression of MCU-DN,
or addition of PF-431396 (2, 65) (Fig. 8D, E). In addition, the
Phe-induced proapoptotic protein release was confirmed by
detecting cytochrome C in enriched cytosolic and mitochon-
drial fractions (Fig. 8F). Furthermore, significant activation of
caspase 3 was observed following prolonged Phe stimulation,
consistent with the idea that a1-ARS initiated destructive ap-
optotic cascades following proapoptotic protein release (Fig.
8G). The results from Figure 8 indicate that Phe stimulation
induces activation of apoptotic signaling cascades through the
a1-AR-Pyk2-MCU-ROS signaling cascade in H9c2 cells.
a1-AR-Pyk2 signaling triggers mSO generation
and cell death in native cardiomyocytes
Wenext determinedwhether this cell death signaling through
the a1-AR-Pyk2-MCU-mROS cascade occurs in ACMs. We
used mitochondria-targeted circularly permuted YFP (mt-
cpYFP) to monitor mSO before and after Phe stimulation. This
biosensor was recently reported from our groups, which can
detect a stochastic and transient superoxide burst from either
single or restricted clusters of interconnected mitochondria or
isolated mitochondria (termed as a ‘‘mitochondrial superoxide
flash’’ (mSOF)) (73). The mSOF generation is a result of a
small increase in constitutive ROS production in mitochondria,
which transiently opens a large channel of mPTP to evoke
transient DJm depolarization, and subsequently stimulates the
ETC to produce a burst in O2
- production. Using this biosensor,
we found that Phe significantly increased the frequency of
mSOF in ACMs (Fig. 9A, B). Pretreatment with prazosin or
PF-431396 inhibited the increase of mSOF induced by Phe,
indicating that the Phe-induced mSO generation is mediated
through the a1-AR-Pyk2 signaling pathway (Fig. 9A, B).
Furthermore, we examined whether a1-AR-Pyk2-mROS
signaling initiates destructive apoptotic cascades in ACMs.
Significant caspase 3 activation was observed after 30min of
Phe stimulation, consistent with the results observed in H9c2
cells (Fig. 9C), but 30min of Phe stimulation did not increase
cardiomyocyte death (data not shown). Next, we observed the
ACM viability after Phe stimulation up to 24 h of treatment
by cell morphology (counting the number of rod-shaped
cells) under a light microscope (Fig. 9D and Supplementary
Fig. S14). We found that over 6 h of Phe stimulation signif-
icantly increased ACM death. Conversely, pretreatment with
prazosin or PF-431396 inhibited the increase of cell death
induced by Phe. We also found that ACMs with abnormal
morphology after Phe treatment had a higher activity of
caspase-3/7, confirming that this Phe-induced cell death is
mediated via the apoptotic cascade (Fig. 9E, F). The pre-
treatment of prazosin, PF-431396, or miito-TEMPO attenu-
ated cell apoptosis induced by 6 h of Phe treatment. These
data indicate that the a1-AR-Pyk2 signaling pathway induces
cell death in ACMs possibly through an increase in mSO.
FIG. 7. a1-AR-Pyk2 signaling acceler-
ates mitochondrial Ca21 uptake. (A) Ef-
fect of Phe pretreatment on [Ca2 + ]mt and
[Ca2 + ]c in the presence or absence of FAK/
Pyk2 inhibitor (PF). [Ca2 + ]mt (right) and
[Ca2 + ]c (left) after TG stimulation in cells
with or without pretreatment of Phe and PF
are shown. PF was applied before Phe
stimulation (2 h before Phe application).
[Ca2 + ]mt and [Ca
2 + ]c were measured using
Mitycam and Fura-red, respectively (see
Supplementary Materials and Methods sec-
tion). *p< 0.05. (B)Effect of Phe pretreatment
on [Ca2+ ]mt and [Ca
2+ ]c in Pyk2-knockdown
H9c2 cells. Knockdown efficiency is shown in
Supplementary Fig. S13. [Ca2+ ]mt (right) and
[Ca2+ ]c (left) after TG stimulation in cells
with or without transfection of a plasmid
containing siRNA-Pyk2 are shown. *p< 0.05.
To see this illustration in color, the reader is
referred to the web version of this article at
www.liebertpub.com/ars
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Discussion
In this study, we identified a signaling pathway that regulates
mitochondrial Ca2+ uptake, ROS production, and apoptotic
signaling through a posttranslational modification of MCU
(Fig. 10). Specifically, we found that Pyk2 activated down-
stream of a1-ARS, translocates into the mitochondria matrix,
where it directly phosphorylates MCU tyrosine residue(s),
which leads to an increase in the number of functional tetra-
meric MCU channels by promoting MCU oligomerization.
FIG. 8. a1-AR-Pyk2-MCU signaling increases mROS levels and initiates apoptotic signaling in H9c2 cells. (A)
Mitochondrial superoxide (mSO) levels induced before and after Phe stimulation (30min, 100lM) in H9C2 cells measured
by MitoSOX-Red in the presence or absence of Pyk2 inhibitor PF-431396 (PF). Scale bar, 20 lm. (B) Left: PF or Mito-
TEMPO pretreatment prevented Phe-induced increases in mSO level. *p < 0.05, compared to the control cells treated with
DMSO (vehicle) before Phe stimulation. Middle: Pyk2 knockdown prevented Phe-induced increases in mSO level.
*p < 0.05, compared to the control cells transfected with control siRNA vector. Right: Overexpression of MCUB prevented
Phe-induced increases in mSO level, whereas overexpression of MCU enhanced this effect. *p < 0.05, compared to the
control cells transfected with pcDNA3.1 empty vector before Phe stimulation. #p < 0.05. N.S., not significant. (C) Sub-
cellular localization of Smac-GFP before and after Phe stimulation (100 lM, 30min). Scale bars, 10 lm. (D) Time de-
pendence of outer mitochondrial membrane (OMM) permeabilization by Phe using Smac-GFP punctate/diffuse index in the
presence or absence of prazosin (Praz), PF-431396 (PF), or MCU-DN overexpression (MCU-DN). FCCP-treated cells are
shown as a positive control (yellow). (E) Summary data of (D) at 35min. *p < 0.05 compared to control cells (nontreated
cells). (F) Time-dependent cytochrome C release from mitochondria to cytosol by a1-AR stimulation. Cells were stimulated
with 100 lM Phe and cytosolic and mitochondria-enriched fractionations were prepared. WCL were also blotted to show the
total amount of cytochrome C (right panel). SERCA2 and VDAC were used to confirm the purity of the cytosolic (including
SR/ER) and mitochondrial fractions, respectively. The blots shown are representative of 3 replicates. (G) Left: Time-
dependent caspase 3 activation by a1-AR signaling. Cells were stimulated by 100 lM Phe for 30min or 60min and WCL
were prepared to detect procaspase 3 and cleaved caspase 3. Caspase 3 activity was evaluated by the cleaved caspase
3/procaspase 3 ratio. Right: Summary data. p < 0.05 compared to nontreated cells (0min). To see this illustration in color,
the reader is referred to the web version of this article at www.liebertpub.com/ars
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Moreover, this a1-AR-Pyk2-MCU signaling cascade enhances
mitochondrial Ca2+ uptake, mSO generation, and proapoptotic
protein release, which initiates the apoptotic cascade and finally
leads to cardiomyocyte death (Fig. 9). These results provide
new insights into the molecular basis of adrenergic modulation
of mitochondrial Ca2+ handling and apoptosis. Furthermore,
the results of this study unveil a new pathway that could be
targeted for the development of novel drugs to protect against
the pathophysiological conditions, where increased a1-ARS
(36) and mitochondrial injury (25) are known to coexist.
Molecular mechanism underlying enhanced
mitochondrial Ca2+ uptake by a1-AR-Pyk2-dependent
phosphorylation of MCU
We showed here that Pyk2 activation during a1-ARS in-
creases mitochondrial Ca2+ uptake through tyrosine phos-
phorylation of MCU, which enhances MCU oligomerization.
This evidence strongly supports the hypothesis that Pyk2-
mediated MCU oligomerization is directly linked to an in-
crease in mitochondrial Ca2+ uptake following a1-ARS. We
also confirmed the MCU topology at IMM and detailed
mPyk2 submitochondrial localization: (i) MCU termini are
located at the matrix side as reported (9, 11, 46), (ii) mPyk2 is
predominantly localized in the matrix, and (iii) Phe stimu-
lation induces Pyk2 translocation from the cytosol to matrix.
This observation suggests that Pyk2 can interact with MCU
from the matrix side and directly phosphorylate the channel
on either the N- or C-termini, which are known to be im-
portant for channel function (12). Recent broad screening of
Pyk2-specific substrates using phosphoproteomics to identify
consensus substrate motifs for Pyk2 has not yet been estab-
lished (6). Human MCU contains 15 tyrosine residues; 5 in
the N-terminus and 6 in the C-terminus, which are conserved
across all eukaryotic species. No tyrosine residues are located
in the pore-forming region (14). However, only three of these
tyrosine residues (Y158 at N-terminus, Y289, and Y317 at C-
terminus) are predicted to be potential PTK phosphorylation
sites using the NetPhos 2.0 phosphorylation prediction pro-
gram (5) and only one of these sites (Y289) is predicted to be
a potential FAK/Pyk2-specific phosphorylation site using the
Group-based Prediction System (74). Interestingly, basal
FIG. 9. a1-AR-Pyk2 signaling accelerates mSO generation and initiates cell death in adult cardiomyocytes. (A)
Representative images of mSO flashes (mSOF) observed in ACMs after Phe stimulation (10min, 100lM with 1 lM
propranolol) by using mitochondrial-targeted cpYFP (see Supplementary Materials and Methods section). (B) Summary
data of mSOF frequency. Pretreatment of prazosin (Praz) (30min, 1lM) or PF-431396 (PF) (2 h, 10 lM) efficiently inhibits
the increase of mSOF induced by Phe. mSOF were collected from 18 cells isolated from three rats. *p< 0.05. Scale bar,
10 lm. (C) Top: Caspase 3 activation by a1-AR signaling. Cells were stimulated by Phe for 30min and WCL were prepared
to detect procaspase 3 and cleaved caspase 3. Caspase 3 activity was evaluated by the cleaved caspase 3/procaspase 3 ratio.
Bottom: Summary data. (D) Top: Six-hour treatment with Phe increased ACM death. Cell variability was monitored by
cardiomyocyte morphology. Pretreatment of Praz or PF efficiently inhibits the increase in cell death induced by Phe.
Bottom: Summary data. *p < 0.05. (E) Phe induces apoptosis in primary cultured cardiomyocytes. The pretreatment of Praz
(30min, 1 lM), PF (2 h, 10 lM), or Mito-TEMPO (1 h, 1 lM) attenuated cell apoptosis induced by 6-h Phe treatment.
Apoptosis was detected by confocal (exitation/emission:488 nm/525 nm) in live cells after staining with a fluorogenic
substrate for activated caspase-3/7 (CellEvent Caspase-3/7 Green Detection Reagent) (see also Supplementary Materials
and Methods section). Cell morphology was also observed under brightfield. As a positive control, cells were treated by
staurosporine (Stauro, 1 lM, 6 h). Images obtained from cells without staining with the detection reagent were also shown as
a negative control. Scale bars, 200lm. (F) Summary data of (E). Images were randomly collected from 11–14 image fields
from two rats. *p < 0.05. To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars
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Y289 phosphorylation was reported following mass spec-
troscopy of human tissue (PhosphoSite) (32, 33). Future
studies are needed to definitively determine Pyk2-specific
phosphorylation site(s) in MCU and to test the functional
importance of these sites using nonphosphorylation and
phosphorylation mimetic MCU mutants. In addition, since
the basal tyrosine phosphorylation of MCU was not com-
pletely abolished by Mito-TEMPO or siRNA-Pyk2 applica-
tion (Fig. 3 and Supplementary Fig. S7), suggesting that not
only Pyk2 but also other PTK in the mitochondrial matrix
(e.g., Src) might regulate the basal tyrosine phosphorylation
level of MCU in situ (28). Two potential CaMKII phos-
phorylation motifs in the N-terminus of MCU were identified
using a nonphosphomutagenesis approach and mutation of
these sites abolishes CaMKII-dependent activation of MCU
current in mitoplast patch-clamp experiments (38). In this
study, we also tested the effect of b-AR signaling on
[Ca2+ ]mt, which can activate a variety of serine/threonine
kinase, including CaMKII, but this signaling did not signifi-
cantly alter TG-induced [Ca2+ ]mt elevation in H9c2 cells
(Supplementary Fig. S5C). The amount of mitochondrial
Ca2+ uptake is generally regulated by the magnitude of
[Ca2+ ]c elevation in all cell types (56). Therefore, it is a
reasonable idea that b-AR signaling has a more prominent
effect on the amount of mitochondrial Ca2+ uptake due to its
strong modulation of the cytosolic Ca2+ transient (CaT) size
compared to a1-AR signaling in ACMs. Our observation of
a1-AR-Pyk2-dependent MCU phosphorylation and its chan-
nel activation may serve as a supportive or additional
mechanism for accelerating mitochondrial Ca2+ in response
to the enhanced CaT under the physiological adrenergic
stimulation. In addition, a1-AR might play more significant
roles when b-AR signaling is downregulated, such as during
heart failure. Future study will address the role of a1-AR-
Pyk2-MCU signaling during beat-to-beat CaT and/or in the
presence of main adrenergic signaling, b-AR stimulation
in ACMs.
Our results also do not rule out the possibility that a1-AR-
Pyk2-dependent tyrosine phosphorylation of MCU alters
regulation of MCU by its auxiliary proteins (e.g., MICU1)
(11), which may change its Ca2+ sensitivity and enhance the
mitochondrial Ca2+ uptake rate. Indeed, Phe is capable of
increasing both mROS production and OMM permeability in
the absence of TG-induced global Ca2+ elevation (Figs. 8 and
9). These data suggest that there might be another mechanism
for the enhancement of the mitochondrial Ca2+ clearance by
a1-AR-Pyk2 signaling in addition to the MCU oligomeriza-
tion. In cardiac cells, a1-ARS increases the resting (diastolic)
[Ca2+ ]c levels (34, 44, 61) and/or spontaneous Ca
2+ release
(45) although its effect to peak [Ca2+ ]c is relatively small.
Therefore, after 15min of Phe stimulation, a1-AR-AR-Pyk2
signaling may change the Ca2+ sensitivity of MCU through
channel tyrosine phosphorylation and mitochondria might
accumulate Ca2+ more efficiently under the enhancement of
spontaneous Ca2+ releases from ER/SR and/or the increase of
resting [Ca2+ ]c levels by Phe. Our data using native PAGE
strongly support the idea that the MCU channel is a tetramer
(see also (63)) and that the tetrameric assembly is augmented
by Pyk2-mediated tyrosine phosphorylation (18) (Fig. 6),
although Baughman et al. reported a larger complex (3). The
difference between these two studies may be due to the dis-
tinct solubilization methods used, such that the larger com-
plex may also include additional mtCU auxiliary proteins,
such as MICU1(11). Further studies are needed to clarify
whether tyrosine phosphorylation of MCU modulates the
interaction of the channel pore with its regulatory proteins
and changes its channel property such as Ca2+ sensitivity.
Role of MCU in ROS generation
and proapoptotic protein release
In this study, we found that a1-AR-Pyk2-MCU signaling
induced mROS generation (especially mSOF), proapoptotic
protein release through mitochondrial Ca2+ overload, and
FIG. 10. Working model: Cardiac a1-AR-Pyk2-depen-
dent MCU phosphorylation initiates mitochondrial Ca21
entry, mSO generation, and cell death. To see this illus-
tration in color, the reader is referred to the web version of
this article at www.liebertpub.com/ars
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ultimately, initiating a classic apoptotic signaling cascade
and cell death. In addition, a1-AR-Pyk2-MCU-mediated
mROS generation and mitochondrial release of proapoptotic
proteins were prevented by either a potent FAK/Pyk2 in-
hibitor or expression of MCU-DN/MCUB. These findings
raise the distinct possibility of targeting the Pyk2 activity as a
novel therapeutic strategy to prevent mitochondrial Ca2+
overload, ROS generation, and cell injury (see also next
section).
The alterations in mitochondrial Ca2+ homeostasis are
frequently observed under cardiac pathological conditions
(15, 16, 25), where AR signaling also exists (36). Recently,
GqPCR stimulation, including via a1-AR, was shown to in-
crease ROS in cardiomyocytes that activate ROS-sensitive
downstream signaling processes (e.g., Pyk2 and CaMKII)
(21, 27). However, the detailed mechanism by which a1-ARS
induces oxidative stress is unclear. In this study, we con-
firmed that a1-ARS increases ROS levels, as previously re-
ported in native cardiomyocytes (70). Moreover, we showed
that the main source of ROS generation during Phe stimu-
lation is the mitochondria and Pyk2-MCU signaling is critical
for mSO generation. We also demonstrated that mROS in-
creases the Pyk2 activity and mitochondrial localization
(Supplementary Fig. S9). These data also indicate that per-
sistent a1-ARS activates a vicious cycle of ROS-induced
ROS generation (75) as a result of ROS-sensitive activation
of Pyk2 (Fig. 10).
By being the primary source of cellular ROS production,
mitochondria play a crucial role for ROS signaling both in
physiological and pathophysiological conditions (51, 66, 71).
With sustained elevations in [Ca2+ ]mt, mROS generation and
DJmt depolarization trigger the mPTP opening that leads to
apoptosis (7, 35). Thus, [Ca2+ ]mt is commonly regarded as an
important determinant in cell sensitivity to apoptotic stimuli in
various cell types (64). Sites of intimate ER-mitochondria
contact enable efficient local Ca2+ transmission between the
two organelles, which serves as a potential regulatory site for
apoptotic signaling (60), possibly via [Ca2+ ]mt-ROS-mPTP
pathways (see Figs. 8–10). We reported that the mitochondrial
voltage-dependent anion channel 1 (VDAC1) selectively in-
teracts with the IP3 receptor in the ER to direct the apopto-
tic Ca2+ release signals into mitochondria (13). Finally, we
demonstrate here the direct involvement of Ca2+ influx
throughMCU in the regulation ofmROS generation, apoptotic
signaling, and cell death in native cardiomyocytes (Fig. 9).
In this study, a supraphysiological concentration of an a1-
AR agonist Phe (100 lM) was used for activating the cell
death cascade to mimic the pathophysiological conditions
(e.g., chronic AR stimulation or a neurohumoral injury state).
However, what is the physiological relevance of a1-AR-
Pyk2-MCU signaling? We also tested the concentration-de-
pendent effect of Phe on [Ca2+ ]mt elevation and found that
Phe had a significant effect for activating mitochondrial Ca2+
uptake through MCU in the range of the subphysiological
concentration (EC50y2lM) (Supplementary Fig. S5). We
also showed that a significant reduction in the [Ca2+ ]c tran-
sient was also observed, due to the increased Ca2+ clearance
by mitochondria after a1-ARS in H9C2 cells (Fig. 1E and
Supplementary Fig. S5). These results are consistent with our
previous observation that a1-ARS decreases the Ca
2+ tran-
sient by inhibiting (i) Ca2+ influx into the cell and (ii) by
enhancing the Ca2+ clearance from the cytosol through PTK
activity (53). Recently, we proposed that MCU may serve
as an important mechanism for cytosolic Ca2+ buffering
when [Ca2+ ]c increases at the ER/SR contact sites (17, 54).
Therefore, physiological a1-ARS may regulate/enhance
the Ca2+ uptake by mitochondria, which may promote mi-
tochondrial function and/or more efficient buffering of
cytosolic Ca2+ . However, it is still controversial whether
mitochondrial Ca2+ uptake contributes to the kinetics of beat-
to-beat CaT formation in ACMs although mitochondria oc-
cupy 35% of cytosolic space and are well known to uptake
Ca2+ (62). Shannon et al. estimated that the mitochondria
contribute to only *1% of the total Ca2+ removal from the
cytosol during CaT; SERCA and sarcolemmal Na2+ /Ca2+
exchanger (NCX) are responsible for almost all Ca2+ re-
moval from the cytosol (69). Further studies are required for
quantitatively evaluating the contribution of the a1-AR-
Pyk2-MCU signaling pathway for enhancing the mitochon-
drial Ca2+ buffering capacity during beat-to-beat CaT under
AR stimulation.
a1-AR-Pyk2 signaling as a novel therapeutic target
for preventing mitochondrial Ca2+ overload,
ROS generation, and cardiac injury
Pyk2 is abundantly found in various types of cancers and is
well established as a key regulator of cancer proliferation,
migration, and invasion (42, 42). Therefore, Pyk2 (or FAK) is
a potent therapeutic target for cancer treatment, and cur-
rently, several FAK/Pyk2 inhibitors are already being eval-
uated in clinical trials (68). In cardiomyocytes, Pyk2
regulates the transcription factors that lead to cardiac re-
modeling, including hypertrophy (4, 29, 30). Therefore, Pyk2
is well studied as a component of nuclear signal transduction
in cancer biology and cardiac remodeling. However, essen-
tially, no information is available related to the effect of Pyk2
on mitochondrial functions. Interestingly, Pyk2 contains a
predicted (using Mitoprot (10)) N-terminus mitochondria-
targeting sequence (MSGVSEPLSRVKLGTLRRP), and a
few reports have shown Pyk2 to be localized in mitochondria
(1, 23). However, the functional role of mPyk2 has not been
established. In this study, we confirmed that Pyk2 exists in
the mitochondrial matrix in cardiac cells and found that a1-
ARS leads to activated Pyk2 translocation from the cytosol to
mitochondrial matrix. Moreover, we showed that mPyk2
regulates MCU and initiates proapoptotic protein release
from mitochondria. Although potent FAK/Pyk2 inhibitors
(e.g., PF-431396 and PF-562271) are widely used in the field
of cancer research, there are no reports regarding the effects
of these drugs in heart disease and mitochondrial injury. Our
results suggest that the small-molecule Pyk2/FAK inhibitors
or Pyk2 knockdown, may prevent mitochondrial Ca2+ over-
load, mROS generation, proapoptotic protein release, and
cell death in the cardiomyocytes during sustained a1-ARS or
in the specific pathophysiological conditions where [Ca2+]c
overload and ROS overproduction coexist (e.g., ischemic–
reperfusion).
Recently, Pyk2 was shown to be activated in human no-
ischemic heart failure (40). However, in heart failure, it has
been well reported that there is a significant elevation of
cytosolic Na2+ concentration ([Na2+ ]c), which enhanced
cytosolic Ca2+ extrusion from the cell during diastole
through NCX and reduced the [Ca2+ ]c transient (52). In
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addition, the [Na2+ ]c elevation and mitochondrial NCX ac-
tivity in heart failure dictate mROS generation through a
decrease in the mitochondrial Ca2+ uptake (50). Indeed,
several studies showed that mitochondrial Ca2+ uptake is
reduced in failing cardiomyocytes (43, 47). These reports
demonstrated that elevated [Na+ ]c and mitochondrial NCX
activity also critically contribute to decreased [Ca2+ ]mt, es-
pecially during heart failure. Since we did not observe the
detailed relationship between the Pyk2-dependent MCU
regulation and [Na2+ ]c or resting [Ca
2+ ]c in this study, it is
still not clear whether activated Pyk2 during heart failure has
a significant impact on the MCU function.
Limitation of this study
In this study, most of the experiments were performed in
cultured cell lines. While important experiments validate
using native cardiomyocytes, we still need to take into ac-
count that our finding cannot be directly applicable to the
in vivo situation. Animal models such as the neurohumoral
injury model using the a1-AR agonist will be indispensable
for exploring the role of the cardiac a1-AR-Pyk2-MCU sig-
naling pathway in physiological and pathophysiological
conditions in vivo as well as validating the Pyk2 inhibition as
a possible novel therapeutic strategy for preventing mito-
chondrial injury and cell death.
Conclusion
This study is the first to investigate the regulation of MCU
by cardiac adrenergic signaling. Elucidation of these regu-
latory mechanisms may lead to the design of novel targets for
the pharmacological management of heart failure, where
chronic adrenergic stimulation, mitochondrial injury, oxida-
tive stress, and myocardial death are present.
Materials and Methods
An expanded fully described Materials and Methods sec-
tion is available in Supplementary Data.
Cell cultures
H9c2 cells and HEK293T cells were maintained, trans-
fected with plasmids, and used for experiments (37, 53, 54).
HEK293T-MCU-Flag cells were generated by transecting
with pcDNA3.1(+ )-MCU-Flag and maintained in the pres-
ence of G-418 (53). NCMs and ACMs were isolated from
Sprague-Dawley rats, plated, cultured, and used for experi-
ments (37). NCMswere transfected with plasmids and ACMs
were infected with adenovirus (17, 37). All animal experi-
ments were performed in accordance with the Guideline on
Animal Experimentation of Thomas Jefferson University
(TJU). The study protocol was approved by the Animal Care
Committee of TJU. The investigation conformed to the
Guideline for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH).
Mitochondrial protein isolation, Western immunoblot
analysis, in vitro kinase, and binding assay
Whole cell lysates and mitochondria-enriched and cyto-
solic proteins were prepared (53). For electrophoresis under
nondissociating conditions, mitochondrial proteins or whole
cell lysates were separated by 10% polyacrylamide gel
(Native-PAGE) (63). IP (37), in vitro binding (72), and kinase
assays (37) were performed as described previously.
Live cell imaging in confocal microscopy
and image analysis
The [Ca2+ ]mt measurement using mitochondria-targeted
Ca2+ biosensor Mitycam (39, 53), [Ca2+ ]c measurement us-
ing Fura-Red (53), FRET measurement (63), mSO mea-
surements by MitoSOX-Red (53), visualizing the release of
mitochondrial intermembrane space proteins (49), measure-
ment of mSOF by mT-cpYFP (73), detection of caspases 3/7
activity (48) were performed in live cells using the laser
scanning confocal microscope (Olympus, Tokyo, Japan).
There were no significant changes in the initial Mitycam
fluorescence levels between the different experimental set-
tings used in this study (see Supplementary Fig. S15). All
images were analyzed with ImageJ software (NIH).
Data and statistical analysis
All results are shown as mean standard error. Unpaired
Student’s t-test was performed for two data sets. For multiple
comparisons, one-way ANOVA followed by the post hoc
Tukey test was performed. Statistical significance was set as a
p value of <0.05.
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Abbreviations Used
a1-AR¼ a1-adrenoceptor
a1-ARS¼ a1-adrenoceptor stimulation
DJm¼mitochondrial membrane
potential
ACM¼ isolated adult cardiomyocytes
[Ca2+]c¼ cytosolic Ca2+ concentration
[Ca2+]mt¼mitochondrial matrix Ca2+
concentration
CaMKII¼Ca2+/calmodulin-dependent
protein kinase II
CCDC109A¼ coiled-coil domain-containing
protein 109A
Cyp-D¼ cyclophilin D
DN¼ dominant negative
ER¼ endoplasmic reticulum
FAK¼ focal adhesion kinase
FCCP¼ carbonyl cyanide
4-(trifluoromethoxy)
phenylhydrazone
FRET¼ Fo¨rster resonance energy
transfer
GqPCR¼Gq-protein coupling receptor
HEK293T-MCU-Flag cells¼HEK293T cells stably
overexpressing MCU-Flag
IMM¼ inner mitochondrial
membranes
IP¼ immunoprecipitation
KD¼ kinase dead
MCU¼mitochondrial Ca2+
uniporter pore
mPTP¼mitochondrial permeability
transition pore
mPyk2¼mitochondrial Pyk2
mROS¼ROS production in
mitochondria
mSO¼mitochondrial superoxide
mSOF¼mitochondrial superoxide
flashes
mtCU¼mitochondrial Ca2+ uniporter
mt-RFP¼mitochondria-targeted RFP
NCM¼ neonatal cardiomyocyte
OMM¼ outer mitochondrial
membranes
Phe¼ phenylephrine
PK¼ Proteinase K
P-Tyr¼ phosphotyrosine
Pyk2¼ proline-rich tyrosine kinase 2
ROS¼ reactive oxygen species
SERCA¼ sarcoendoplasmic reticulum/
endoplasmic reticulum
Ca2+-ATPase
Smac¼ second mitochondrial-derived
activator of caspases
SR¼ sarcoplasmic reticulum
TG¼ thapsigargin
VDAC¼ voltage-dependent anion
channel
WCL¼whole cell lysates
ADRENERGIC REGULATION OF MITOCHONDRIAL Ca21 UNIPORTER 879
